China’s Xi speaks with Trump by phone, discusses Taiwan and bilateral ties
DUBLIN - Investment firm Geode Capital Management, LLC has disclosed a 2.24% ownership position in Avadel Pharmaceuticals plc, according to a regulatory filing published Thursday.
The filing, made under the Irish Takeover Panel rules, reveals that Geode holds 2,191,042 ordinary shares in the pharmaceutical company as of November 5, 2025.
The disclosure also details a recent transaction in which Geode purchased 529 additional Avadel shares at a price of $18.96 per unit.
The filing was submitted as an opening position disclosure in accordance with Rule 8.3 of the Irish Takeover Panel Act, which requires persons with interests representing 1% or more of a company's securities to disclose their holdings.
Geode Capital, a global investment management firm, indicated in the filing that it does not have any cash-settled derivatives, stock-settled derivatives, or other arrangements related to Avadel securities.
The disclosure comes amid potential takeover activity involving Avadel Pharmaceuticals, though no specific details about any offers were included in the filing. Geode stated it is not making disclosures in respect of any other party to a potential offer.
Avadel Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medications for central nervous system disorders.
This information was reported in a Form 8.3 filing submitted to the Irish Takeover Panel.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.